Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

This study investigates the incidence and clinical outcomes of myocarditis following BNT162b2 mRNA COVID-19 vaccination in a large Israeli healthcare organization. Among 2.5 million vaccinated individuals aged 16 or older, 54 cases of myocarditis were confirmed, yielding an estimated incidence of 2.13 cases per 100,000 persons. The highest incidence (10.69 per 100,000) occurred in males aged 16–29 years. Most cases were mild (76%) or moderate (22%), with one severe case involving cardiogenic shock. Symptoms primarily included chest pain (81%), and left ventricular dysfunction was observed in 29% of cases, with normalization in follow-up for some patients. The findings suggest a low but notable risk of myocarditis post-vaccination, particularly in young males, with generally favorable short-term outcomes.

This study investigates the incidence and clinical outcomes of myocarditis following BNT162b2 mRNA COVID-19 vaccination in a large Israeli healthcare organization. Among 2.5 million vaccinated individuals aged 16 or older, 54 cases of myocarditis were confirmed, yielding an estimated incidence of 2.13 cases per 100,000 persons. The highest incidence (10.69 per 100,000) occurred in males aged 16–29 years. Most cases were mild (76%) or moderate (22%), with one severe case involving cardiogenic shock. Symptoms primarily included chest pain (81%), and left ventricular dysfunction was observed in 29% of cases, with normalization in follow-up for some patients. The findings suggest a low but notable risk of myocarditis post-vaccination, particularly in young males, with generally favorable short-term outcomes.